Stock performance
Search documents
SLB Limited's Stock Performance and Institutional Interest
Financial Modeling Prep· 2026-01-07 20:00
Core Viewpoint - SLB Limited is experiencing positive sentiment from institutional investors, reflected in increased holdings and a raised price target by Susquehanna, indicating a favorable outlook for the company's future performance [1][2][3]. Group 1: Institutional Investor Activity - Community Trust and Investment Co. increased its holdings in SLB by 4.3% during Q3, now owning 426,794 shares valued at approximately $14.7 million [2]. - Synergy Asset Management LLC doubled its stake in SLB, now holding 80,830 shares valued at $2.7 million [3]. - Bank Pictet and Cie Europe AG significantly increased its stake by 1,937.4%, now holding 996,948 shares, indicating growing interest among institutional investors [3]. Group 2: Stock Performance and Market Metrics - SLB's current stock price on the NYSE is $43.18, reflecting a slight decrease of 1.03% or $0.45 [4]. - The stock has traded between $42.72 and $43.90 today, with a yearly high of $45.16 and a low of $31.11, indicating volatility [4]. - The company's market capitalization is approximately $64.5 billion, with a trading volume of 2,436,972 shares, showing active investor interest [4].
Weybosset Research & Management Waves Goodbye to $3.3 Million Worth of MaxLinear Shares
Yahoo Finance· 2026-01-07 16:41
This transaction by Weybosset Research & Management LLC, a Rhode Island-based financial advisory firm, could signal a shift in institutional support for MaxLinear. Here's what investors need to know.MaxLinear, Inc. is a semiconductor company specializing in advanced communications systems-on-chip for broadband, wireless, and industrial sectors. The company leverages expertise in RF and mixed-signal integration to deliver highly integrated solutions for high-speed connectivity applications. Its diversified c ...
Wells Fargo & Company (WFC) Maintains "Outperform" Rating by Evercore ISI
Financial Modeling Prep· 2026-01-06 21:00
Core Viewpoint - Evercore ISI maintains an "Outperform" rating for Wells Fargo, indicating confidence in the stock's future performance and raising the price target from $107 to $110, suggesting expectations of growth [2][5]. Company Overview - Wells Fargo & Company, trading under the symbol WFC on the NYSE, is a significant player in the financial services industry, offering a variety of services including banking, investment, and mortgage products [1]. - The company competes with major financial institutions such as JPMorgan Chase and Bank of America [1]. Stock Performance - As of January 6, 2026, Wells Fargo's stock was priced at approximately $95.60, with a slight decrease to $95.66, reflecting a drop of 0.72 or about -0.75% [2][3]. - The stock has experienced a trading range between $95.07 and $95.845 on the same day [3]. Market Capitalization and Trading Volume - Wells Fargo's market capitalization is approximately $311 billion, indicating a strong presence in the financial sector [4]. - The trading volume for WFC is reported at 3,281,029 shares, demonstrating active investor interest [4]. Volatility - Over the past year, Wells Fargo's stock has seen a high of $97.76 and a low of $58.42, highlighting its volatility in the market [4].
Archer-Daniels-Midland’s Quarterly Earnings Preview: What You Need to Know
Yahoo Finance· 2026-01-06 15:36
Headquartered in Chicago, Illinois, Archer-Daniels-Midland Company (ADM) is a major food processing and agricultural commodities trading corporation. The company operates a global network of processing plants and crop procurement facilities, where it transforms cereal grains and oilseeds into a wide range of products for the food, beverage, nutraceutical, industrial, and animal feed markets. ADM also provides agricultural storage and transportation services and is a significant player in global agribusines ...
Tesla stock erases early gains: why investors turned sour on Q4 deliveries
Invezz· 2026-01-02 15:35
Tesla reported a second consecutive annual decline in vehicle sales, and while the market initially appeared unfazed, selling pressure mounted as investors digested the weaker delivery numbers amid a ... ...
These stocks fell hard in 2025, but analysts see as much as 65% upside for them in 2026
MarketWatch· 2025-12-29 14:59
Although the S&P 500 has returned 19.3% so far this year, dozens of stocks are showing significant declines for 2025. ...
Paychex (PAYX) Reports Q2 Earnings: What Key Metrics Have to Say
ZACKS· 2025-12-22 15:31
Core Insights - Paychex reported revenue of $1.56 billion for the quarter ended November 2025, reflecting an 18.3% increase year-over-year and a surprise of +0.22% over the Zacks Consensus Estimate of $1.55 billion [1] - Earnings per share (EPS) for the quarter was $1.26, up from $1.14 in the same quarter last year, with an EPS surprise of +1.61% compared to the consensus estimate of $1.24 [1] Financial Performance Metrics - Average investment balance for funds held for clients was $5.35 billion, exceeding the three-analyst average estimate of $5.22 billion [4] - Average interest rates earned on funds held for clients was 3.5%, slightly above the three-analyst average estimate of 3.4% [4] - Average investment balance for corporate cash equivalents and investments was $1.68 billion, surpassing the $1.55 billion average estimate based on two analysts [4] - Average interest rates earned on corporate cash equivalents and investments was 3.9%, below the two-analyst average estimate of 4.1% [4] - Revenue from Management Solutions was $1.17 billion, slightly below the $1.18 billion average estimate from five analysts, but represented a +21.1% year-over-year change [4] - Revenue from interest on funds held for clients was $54.3 million, exceeding the $45.65 million estimated by five analysts, marking a +50.4% change year-over-year [4] - Total service revenue was $1.5 billion, slightly below the $1.51 billion estimated by five analysts, with a +17.4% year-over-year change [4] - Revenue from PEO and Insurance Solutions was $336.9 million, above the five-analyst average estimate of $330.83 million, representing a +6% year-over-year change [4] Stock Performance - Shares of Paychex have returned +0.7% over the past month, underperforming the Zacks S&P 500 composite's +3% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]
Nike, Insmed, And Arm Are Among Top 10 Large Cap Losers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio? - ARM Holdings (NASDAQ:ARM), BitMine Immersion (AMEX:BMNR), Insmed (NASDAQ:INSM),
Benzinga· 2025-12-21 15:01
These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?Nike, Inc. (NYSE:NKE) decreased 12.81% this week after the company reported a 17% decline in Greater China sales in the second quarter. Also, multiple analysts lowered their price forecast on the stock.Arm Holdings plc (NASDAQ:ARM) fell 9.77% this week after Goldman Sachs downgraded the stock from Neutral to Sell and lowered the price forecast from $160 to $120. Also, B of A Securities lowered the price forecas ...
Why Is Jack In The Box (JACK) Up 27% Since Last Earnings Report?
ZACKS· 2025-12-19 17:31
It has been about a month since the last earnings report for Jack In The Box (JACK) . Shares have added about 27% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Jack In The Box due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.Jack in the Box Q4 Earnings Lag & Revenue ...
Humana Inc. (NYSE:HUM) Overview: Stock Performance and Market Outlook
Financial Modeling Prep· 2025-12-18 18:06
Core Viewpoint - Humana Inc. is a prominent health insurance provider in the U.S., recently rated "Underperform" by Morgan Stanley, which has lowered its price target for the company [1][6]. Financial Performance - Morgan Stanley adjusted Humana's price target from $277 to $262, while the stock was priced at $260.28, reflecting a slight increase of $2.12 or 0.82% [2][6]. - Humana's stock has fluctuated between $256.35 and $266.08 during the day, with a yearly high of $315.35 and a low of $206.87. The company's market capitalization is approximately $31.3 billion [4][6]. Contracts and Partnerships - The U.S. Defense Department awarded Humana a $7.3 billion contract for health care and administrative support services, indicating a strong relationship with the Pentagon and potential positive impacts on future financial performance [3][5][6]. Market Activity - Today's trading volume for Humana is 1,073,203 shares, indicating significant investor interest despite the "Underperform" rating from Morgan Stanley [5][6].